Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).

Arthritis Res Ther · 2014 · PMC4243296 · PMID 25359150

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

Pateclizumab failed to reach statistical significance for other key secondary efficacy endpoints, including ACR20 and ACR70.

also in 6,035 other papers

did not reach statistical significanceno p-value reported

Results Pateclizumab reduced the DAS28(4)-ESR response (−1.89) at 12 weeks, however, this did not reach statistical significance compared to placebo (−1.54), while adalimumab (−2.52) differed significantly from both placebo and pateclizumab.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.